Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H: TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013, 126:931–937.PubMedCrossRef 23. Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, Luu B, Jones DT, Garzia L, Dubuc AM, Zhukova Erastin manufacturer N, Vanner R, Kros JM, French PJ, Van Meir EG, Vibhakar R, Zitterbart K, Chan JA, Bognar L, Klekner A, Lach B, et al.: TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol

2013, 126:917–929.PubMedCentralPubMedCrossRef 24. Scott GA, Laughlin TS, Rothberg PG: Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol 2014, 27:516–523.PubMedCrossRef

25. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P: Frequency of TERT promoter mutations in human cancers. Nat Commun 2013, 4:2185.PubMedCrossRef 26. Goutagny S, Nault JC, Mallet M, Henin D, see more Rossi JZ, Kalamarides M: High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 2014, 24:184–189.CrossRef 27. Schneider-Stock R, Jaeger V, Rys J, Epplen JT, Roessner A: High learn more telomerase activity and high HTRT mRNA expression differentiate pure myxoid Epothilone B (EPO906, Patupilone) and myxoid/round-cell liposarcomas. Int J Cancer 2000, 89:63–68.PubMedCrossRef 28. Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel

RR, Zaffaroni N: Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006, 66:8918–8924.PubMedCrossRef 29. Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Sugita T, Ochi M: Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas. J Exp Clin Cancer Res 2012, 31:5.PubMedCentralPubMedCrossRef 30. Schneider-Stock R, Boltze C, Jager V, Epplen J, Landt O, Peters B, Rys J, Roessner A: Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J Pathol 2003, 199:517–525.PubMedCrossRef 31. Yan P, Benhattar J, Coindre JM, Guillou L: Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int J Cancer 2002, 98:851–856.PubMedCrossRef 32. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998, 58:4168–4172.PubMed 33.